Navigation Links
MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting

MOUNTAIN VIEW, Calif., June 05, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster presentation, which was accepted as a late-breaker, is entitled Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo(TM) Inhaler), Poster ID S77, and will be presented on Saturday, June 9, 2007 from 12:00 to 1:00pm CDT. In addition, the Company also has three other poster presentations available for viewing at the conference.

    Details for the three presentations are as follows:


    -- Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel

       System (Tempo(TM) Inhaler); Poster ID F07; June 8, 12:30 to 1:30pm CDT.


    -- Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites

       Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel

       System (Tempo(TM) Inhaler); Poster ID F08; June 8, 12:30 to 1:30pm CDT.


    -- (5-HT, Adrenergic, Dopaminergic) Receptor Binding: Implications for

       Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System

       (Tempo(TM) Inhaler); Poster ID S67; June 9, 12:00 to 1:00pm CDT.


MAP Pharmaceuticals is developing a series of inhaled respiratory and systemic drug product candidates delivered with the Tempo inhaler. The first of these product candidates is MAP0004, a systemic migraine treatment designed to provide faster and more consistent relief than current non-injectable therapeutics. In early human studies, MAP0004 delivered therapeutic blood levels within ten minutes of inhalation, similar to those seen only after intravenous injection. This performance will potentially allow MAP0004 to mimic both the efficacy and blood levels of inj ectable therapy, offering fast relief without injections. By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs of the large, underserved population of migraine sufferers with MAP0004.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and neurological diseases. The Company has announced positive results from Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, ljohnson@mappharma.com

Web site: http://www.mappharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint Medicines ... discovering and developing targeted kinase medicines for patients ... its ongoing Phase 1 trial evaluating BLU-285, an ... advanced systemic mastocytosis (SM). Blueprint Medicines is developing ... D816V mutant KIT. Approximately 90 to 95 percent ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... NEW ORLEANS , Dec. 2, 2016  Former Attorney ... Foti, Jr., Esq. , a partner at the law firm ... has commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in ... an "antitrust investigation by the Justice Department, begun about two ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... on the perils of heroin that was watched live by 1 million viewers ... I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School of ...
(Date:12/2/2016)... ... 02, 2016 , ... More than 100 business, civic, community ... attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, hosted ... operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, Stillman ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
Breaking Medicine News(10 mins):